Bristol Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) to treat locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
The US pharma major acquired the oral therapy - a tyrosine kinase inhibitor (TKI) targeting ROS1 oncogenic fusions - from Turning Point Therapeutics (Nasdaq: TPTX) for $4.1 billion last year.
This approval is based on the pivotal TRIDENT-1 trial, in which Augtyro successfully achieved a high objective response rate and durable response.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze